Startups
2021
ENDOLIPID THERAPEUTICS SLPeptides Mimicking the SHBG Function - Innovation to reduce Ectopic Fat Accumulation
Address
Passeig de la Vall d'Hebron 119-129, 08035 Barcelona, Spain
Finance Data
CERCA ownership
Barcelona, Spain
2002
Vall d’Hebron Institut de Recerca (VHIR)
Status & Deeptech areas
Company Status & Company Deeptech AreasCurrent company status
DeepTech Area
Spinoff information
Company Description
Reduce ectopic fat
Mimicking SHBG: A new mechanism of action to reduce ectopic fat, with strong science fundament and interesting applications
Cellulite and NASH
Peptides EDL3D and EDL6D for celluite and NASH applications
2-Speed business model
Business model with short- and long-term assets that allow an early return in 2023
Mimicking SHBG: A new mechanism of action to reduce ectopic fat, with strong science fundament and interesting applications
Cellulite and NASH
Peptides EDL3D and EDL6D for celluite and NASH applications
2-Speed business model
Business model with short- and long-term assets that allow an early return in 2023
Product description
The ENDOLIPID Technology. SHBG-mimic Peptides
Peptides mimicking SHBG are useful to treat fatty liver diseases and reduce cellulite. Therapeutic and dermocosmetic applications.
Two peptides, EDL3D (Cellulite) is ready for co-development and EDL6D (NASH) is in PoC.
EDL3D – Cellulite.
New MoA with strong science fundaments
Strong lipolytic effect
Favourable safety profile
Peptide ready for co-development and license-out
ADL6D Nash
EDL6D – NASH.
New MoA with strong science fundaments
Outstanding efficacy hitting the 4 causes of the disease
Favourable safety profile
Peptide in in vivo validation in mice (PoC)
Peptides mimicking SHBG are useful to treat fatty liver diseases and reduce cellulite. Therapeutic and dermocosmetic applications.
Two peptides, EDL3D (Cellulite) is ready for co-development and EDL6D (NASH) is in PoC.
EDL3D – Cellulite.
New MoA with strong science fundaments
Strong lipolytic effect
Favourable safety profile
Peptide ready for co-development and license-out
ADL6D Nash
EDL6D – NASH.
New MoA with strong science fundaments
Outstanding efficacy hitting the 4 causes of the disease
Favourable safety profile
Peptide in in vivo validation in mice (PoC)